Showing 7661-7670 of 8649 results for "".
- CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoVhttps://modernod.com/news/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/2478656/CureVac announced that it has enrolled the first participant in the pivotal phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The randomized, observer blind, placebo-controlled phase 2b/3 trial
- US Government to Buy 100 Million More Doses of Moderna’s COVID-19 Vaccinehttps://modernod.com/news/us-government-to-buy-100-million-more-doses-of-modernas-covid-19-vaccine/2478657/Moderna announced that the US government has exercised its option to purchase an additional 100 million doses of the drugmaker’s COVID-19 vaccine candidate mRNA-1273, bringing its confirmed order commitment to 200 million doses in the US. CEO Stéphane Bancel remarked that “we c
- HHS Proposes Changes to HIPAA Privacy Rule to Improve Care Coordinationhttps://modernod.com/news/hhs-proposes-changes-to-hipaa-privacy-rule-to-improve-care-coordination/2478653/The Trump administration proposed changes Thursday to data privacy rules aimed at giving patients more access to their health information and improve care coordination, according to a FierceHealthcare
- FDA Panel Endorses Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/fda-panel-endorses-pfizer-biontechs-covid-19-vaccine/2478650/An FDA advisory panel that convened Thursday to discuss Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 voted 17-4, with one abstention, in favor of authorizing it for emergency use in people 16 years and older. The vote follows the release of briefing documents earlier this week in which F
- No Red Flags in FDA Review of Pfizer, BioNTech’s COVID-19 Vaccine Candidatehttps://modernod.com/news/no-red-flags-in-fda-review-of-pfizer-biontechs-covid-19-vaccine-candidate/2478641/In briefing documents released Tuesday ahead of an FDA advisory committee meeting on December 10, agency staff said that efficacy data submitted by Pfizer and BioNTech in support of BNT162b2 are “consistent” with recommendations previously detailed in guidance on the emergency-use aut
- Biden Builds Out Health Team with Xavier Becerra Named to Lead HHShttps://modernod.com/news/biden-builds-out-health-team-with-xavier-becerra-named-to-lead-hhs/2478635/US President-elect Joe Biden released more of his health team picks on Monday, nominating California Attorney General Xavier Becerra to serve as Secretary of Health and Human Services (HHS). In addition, Vivek Murthy, who was the US Surgeon General from 2014 to 2017, has been selected to return t
- Supply Chain Snags Blamed For Cut to Pfizer COVID-19 Vaccine Rollout This Year: Reporthttps://modernod.com/news/supply-chain-snags-blamed-for-cut-to-pfizer-covid-19-vaccine-rollout-this-year-report/2478626/Pfizer and BioNTech expect to ship only half of the 100 million doses of COVID-19 vaccine they had originally targeted for worldwide delivery this year because of hurdles encountered with the supply chain, according to a report in The Wall Street Journal on Thursday. A person directly in
- Effort To ‘End Blindness’ Marks Milestone With Leading Scientists Recognized For Pioneering Workhttps://modernod.com/news/effort-to-end-blindness-marks-milestone-with-leading-scientists-recognized-for-pioneering-work/2478623/End Blindness 2020, a joint effort by leading scientists and figures from the worlds of business, politics, culture, art, music and entertainment to rid the world of blindness, is about to mark a milestone. On December 14, 2020, 13 scientists will share
- InMed Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoidshttps://modernod.com/news/inmed-licenses-midrops-delivery-technology-from-eyecro-for-the-delivery-of-therapeutic-cannabinoids/2478621/InMed Pharmaceuticals announced that it has secured an exclusive, worldwide license from EyeCRO for its Microemulsion Drug Ocular Penetration System (MiDROPS) eyedrop delivery technology targeting effective, topical administration of cannabinoids to the eye. EyeCRO is a contract research o
- Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)https://modernod.com/news/oyster-point-pharma-submits-a-phase-2-clinical-trial-protocol-to-evaluate-oc-01-nasal-spray-for-neurotrophic-keratitis-nk/2478616/Oyster Point Pharma announced it has submitted to the FDA a protocol to initiate a clinical study in adult patients with neurotrophic keratitis (NK). The submission was made to Oyster Point’s investigational new drug (IND) for OC-01 (varenicline) nasal spray in dry eye disea